US FDA OTC Monograph Meetings Guidance Should Be Familiar To Firms Using NDA Pathway
Executive Summary
Recent draft guidance on scheduling FDA meetings to discuss potential OTC monograph order requests marks step in program overhaul authorized in 2020 legislation, but isn’t a signal for manufacturers, other industry stakeholders to expect meetings soon.
You may also be interested in...
Overhaul To Improve US OTC Monograph Program Could Steer Sponsors To NDA Process
Some would-be sponsors might opt against submitting OMORs because NDA process could offer more room for adjustments and a better chance for success. Absence of assurance in draft guidance of confidentiality for information sponsors share with FDA before submitting OMORs also could influence some to choose NDA process.
US OTC Monograph FY2022 Facility Fees Deadline In June At Amount TBD
Firms making OTC monograph drugs won’t have to pay facility fees twice during FY2021, says Theresa Michele, FDA Office of Nonprescription Drugs director.
US FDA Meets Initial Deadlines In OTC Monograph Overhaul While It's Rebuilding The Program
Authorization was a long time coming for FDA to reform OTC monograph program and streamline process to change formulations, indications or labeling for large majority of drugs available nonprescription. As program is overhauled, monograph updates may seem to be coming just as slowly.